Semaglutide and cancer: A systematic review and meta-analysis
Author:
Publisher
Elsevier BV
Subject
General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference101 articles.
1. Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA adverse event reporting system;Shu;Front Public Health,2022
2. GLP-1 receptor agonists and the risk of thyroid cancer;Bezin;Diabetes Care,2023
3. Differential risk of cancer associated with glucagon-like peptide-1 receptor agonists: analysis of real-world databases;Wang;Endocr Res,2022
4. Glucagon-like peptide-1 analogues and thyroid cancer: an analysis of cases reported in the European pharmacovigilance database;Mali;J Clin Pharm Therapeut,2021
5. Do GLP-1 receptor agonists increase the risk of breast cancer? A systematic review and meta-analysis;Piccoli;J Clin Endocrinol Metab,2021
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Glucagon-like peptide-1 (GLP-1) receptor agonists for weight management: A review for the gynecologic oncologist;Gynecologic Oncology;2024-11
2. Glucagon-like peptide-1 receptor agonists and risk of gastrointestinal cancers: A systematic review and meta-analysis of randomized controlled trials;Pharmacological Research;2024-10
3. What should I consider when prescribing semaglutide for children living with obesity?;Archives of disease in childhood - Education & practice edition;2024-09-06
4. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of developing cancer-related lymphedema following axillary lymph node dissection (ALND);Frontiers in Pharmacology;2024-09-04
5. Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial;The Lancet Diabetes & Endocrinology;2024-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3